JN.1 Novavax COVID-19 Vaccine Now Available in Singapore

SINGAPORE: Starting January 2, 2026, the JN.1 Novavax/Nuvaxovid COVID-19 vaccine will be made accessible at select general practitioner (GP) clinics as part of the national vaccination program, continuing until May 31, 2026. This vaccine serves as an alternative to the LP.8.1 Pfizer-BioNTech and Moderna vaccines, which were introduced in October 2025.

Importance of the JN.1 Novavax Vaccine

The Communicable Diseases Agency (CDA) announced that both vaccine variants are anticipated to provide enhanced protection against severe COVID-19 cases. The JN.1 Novavax vaccine was initially available at certain GP clinics until April 30, following its approval by the Health Sciences Authority for use in individuals aged 12 and older.

Who Should Consider the JN.1 Vaccine?

The CDA emphasizes that those who have not received an additional dose of a COVID-19 vaccine in the last year may benefit from the JN.1 Novavax vaccine. As immunity can wane over time, an extra dose in 2025 or 2026 can significantly bolster defense against severe disease. This recommendation applies to individuals who have received any of the Pfizer-BioNTech, Moderna, or JN.1 Novavax vaccines in 2024 or 2025.

Vaccination Timing and Availability

For individuals opting for the vaccine as an additional dose, it is advised to schedule it approximately one year, but at least five months, after their last vaccination. Appointments can be booked starting Friday.

It is crucial for prospective recipients to note that the cutoff date for receiving the JN.1 Novavax vaccine is May 31, 2026. This is because the manufacturer will discontinue supplying this formulation once the current stock runs out, meaning it will no longer be available under the national vaccination program.

Continuing Options for Vaccination

The LP.8.1 Pfizer-BioNTech and Moderna vaccines will remain available as options. The national vaccination program in Singapore ensures that COVID-19 vaccinations are provided free of charge to all eligible individuals.

Health Recommendations

The CDA cautions that COVID-19 waves will persist, posing risks particularly to older adults and those with underlying health conditions. To enhance their protection against severe illness, the agency strongly encourages individuals aged 60 and above, medically vulnerable populations, and residents in aged care facilities to keep their vaccinations up to date, similar to flu vaccination practices.

For those interested in receiving a COVID-19 vaccine, comprehensive information on vaccination sites and available vaccine types can be found through the designated government website.

Conclusion

The introduction of the JN.1 Novavax COVID-19 vaccine adds an important option in Singapore’s ongoing vaccination efforts. With the emphasis on maintaining immunity, particularly among vulnerable populations, it remains essential for individuals to stay informed and get vaccinated as recommended.